Pasithea Therapeutics rises on positive early-stage data from cancer drug

Pasithea Therapeutics

26/09/2024 13:34

** Shares of drug developer Pasithea Therapeutics  KTTA.O 
rise 64.3% to $6.31 premarket 
    ** KTTA says its experimental cancer drug, PAS-004, was safe
and well tolerated in an early-stage study
    ** Says one heavily pre-treated patient with stage three
colon cancer showed prolonged stable disease  
    ** Co is testing the drug in certain cancer patients whose
tumor has an RAF mutation 
    ** Says no treatment-related adverse events were observed
and no drug-related dose interruptions or discontinuations
    ** Co expects to provide additional trial updates on a
periodic basis as the trial progresses
    ** Up to last close, stock down 48% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))